SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's lab launches Lenalidomide Capsules in US

08 Sep 2022 Evaluate

Dr. Reddy's Laboratories has launched Lenalidomide Capsules, a therapeutic equivalent generic version of Revlimid (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA) in U.S. market. With this volume-limited launch, Dr. Reddy’s is eligible for first-to market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.

Celgene has agreed to provide Dr. Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. in settlement of all outstanding claims of its litigation. The agreed-upon percentages remain confidential. As part of the settlement, Dr. Reddy’s is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.

Dr. Reddy’s Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg, and 25 mg strengths, each in a bottle-count size of 21.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Labs. Share Price

1409.45 59.45 (4.40%)
29-Jun-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1890.00
Dr. Reddys Labs. 1409.45
Cipla 1474.55
Zydus Lifesciences 1116.45
Lupin 2390.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: